Cargando…
In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
Despite the well-demonstrated involvement of both interleukin 2 (IL-2) and interleukin 12 (IL-12) in the activation of host anti-cancer response, the knowledge of IL-2-IL-12 interactions has still to be better investigated. This study was performed to evaluate the effects of subcutaneous (s.c.) low-...
Autores principales: | Lissoni, P., Fumagalli, L., Rovelli, F., Brivio, F., Di Felice, G., Majorca, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150329/ https://www.ncbi.nlm.nih.gov/pubmed/9667674 |
Ejemplares similares
-
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
por: Lissoni, P., et al.
Publicado: (1993) -
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
por: Lissoni, P., et al.
Publicado: (1994) -
Pretreatment serum markers and lymphocyte response to interleukin-2 therapy
por: Fumagalli, L, et al.
Publicado: (1999) -
In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposure
por: Meiler, Flurina, et al.
Publicado: (2008) -
IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8(+) T cells
por: Li, Lei, et al.
Publicado: (2017)